Email this article Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study
- Authors: Lebedkina M.S.1, Fomina D.S.1,2, Mutovina Z.Y.1,3, Mаrkina U.A.1, Bogomolov P.O.4,5, Chulanov V.P.2,6, Lysenko M.A.1,7, Alexeeva E.I.2,8
-
Affiliations:
- City Clinical Hospital №52, Moscow
- Sechenov First Moscow State Medical University (Sechenov University)
- Central State Medical Academy of the President of the Russian Federation
- Vladimirsky Moscow Regional Research Clinical Institute
- Yevdokimov Moscow State University of Medicine and Dentistry
- National Medical Research Center of Tuberculosis and Infectious Diseases
- Pirogov Russian National Research Medical University
- National Medical Research Center for Children's Health
- Issue: Vol 95, No 6 (2023)
- Pages: 494-499
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/133110
- DOI: https://doi.org/10.26442/00403660.2023.06.202297
- ID: 133110
Cite item
Full Text
Abstract
Aim. To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal antibodies – MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with risk factors in real word settings.
Materials and methods. A non-interventional non-comparative observational study with primary prospective data collection included 108 patients with mild to moderate COVID-19 (mean age 61 years), who had risk factors for developing severe disease. All patients (n=108) were treated with a combination of MAB casirivimab and imdevimab intravenous single infusion 1200 mg (600 mg of each component). The efficacy and safety of MAB were assessed at 7, 14, and 28 days after infusion.
Results. Efficacy. Indications for hospitalization by day 7 from the moment of MAB administration were in 0.9% (n=1), by day 14 – in 1.9% (n=2), by day 28 – in 0.9% of patients; to stay in the intensive care units by the 7th day – in 4.6% (n=5), by the 14th day – in 0.9% (n=1), by the 28th day – in 0.9% (n=1) patients. During 28 days of follow up, the need for mechanical ventilation and extracorporeal membrane oxygenation was registered in 2/108 (1.8%) patients. There were no deaths directly related to COVID-19 in the assessed cohort of patients. Safety. By the 28th day of the follow up, no adverse effects due to MAB therapy were registered.
Conclusion. An analysis of the results of a non-interventional observational study summarized in this article showed the high efficacy and safety of virus-neutralizing MAB combination (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with of risk factors for severe COVID-19 in real word settings.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Marina S. Lebedkina
City Clinical Hospital №52, Moscow
Email: roppelt_anna@mail.ru
ORCID iD: 0000-0002-9545-4720
врач – аллерголог-иммунолог Московского городского научно-практического центра аллергологии и иммунологии ГБУЗ «ГКБ №52»
Russian Federation, MoscowDaria S. Fomina
City Clinical Hospital №52, Moscow; Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538
MD, Dr. Sci. (Med.), Associate Professor
Russian Federation, Moscow; MoscowZinaida Y. Mutovina
City Clinical Hospital №52, Moscow; Central State Medical Academy of the President of the Russian Federation
Email: zmutovina@mail.ru
ORCID iD: 0000-0001-5809-6015
канд. мед. наук, врач-ревматолог, зав. ревматологическим отд-нием ГБУЗ «ГКБ №52», доц. каф. общей терапии, кардиологии и функциональной диагностики ФГБУ ДПО ЦГМА УД Президента РФ
Russian Federation, Moscow; MoscowUlyana A. Mаrkina
City Clinical Hospital №52, Moscow
Email: roppelt_anna@mail.ru
ORCID iD: 0000-0002-6646-4233
врач – аллерголог-иммунолог Московского городского научно-практического центра аллергологии и иммунологии ГБУЗ «ГКБ №52»
Russian Federation, MoscowPavel O. Bogomolov
Vladimirsky Moscow Regional Research Clinical Institute; Yevdokimov Moscow State University of Medicine and Dentistry
Email: hepatology@monikiweb.ru
ORCID iD: 0000-0003-2346-1216
канд. мед. наук, рук. отд-ния гепатологии ГБУЗ МО «МОНИКИ им. М.Ф. Владимирского», доц. каф. пропедевтики внутренних болезней, гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
Russian Federation, Moscow; MoscowVladimir P. Chulanov
Sechenov First Moscow State Medical University (Sechenov University); National Medical Research Center of Tuberculosis and Infectious Diseases
Email: ChulanovVP@nmrc.ru
ORCID iD: 0000-0001-6303-9293
SPIN-code: 2336-4545
д-р мед. наук, проф., проф. каф. инфекционных болезней Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет), зам. дир. по научной работе и инновационному развитию ФГБУ НМИЦ ФПИ
Russian Federation, Moscow; MoscowMariana A. Lysenko
City Clinical Hospital №52, Moscow; Pirogov Russian National Research Medical University
Email: alrheumo@mail.ru
ORCID iD: 0000-0001-6010-7975
д-р мед. наук, глав. врач ГБУЗ «ГКБ №52», проф. каф. общей терапии фак-та дополнительного профессионального образования ФГАОУ ВО «РНИМУ им. Н.И. Пирогова»
Russian Federation, Moscow; MoscowEkaterina I. Alexeeva
Sechenov First Moscow State Medical University (Sechenov University); National Medical Research Center for Children's Health
Email: itchermd@gmail.com
ORCID iD: 0000-0002-3874-4721
чл.-кор. РАН, д-р мед. наук, проф., дир. Клинического института детского здоровья им. Н.Ф. Филатова ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет), зав. ревматологическим отд-нием ФГАУ «НМИЦ здоровья детей»
Russian Federation, Moscow; MoscowReferences
- Living with Covid19. NIHR Evidence. 2020. doi: 10.3310/themedreview_41169
- COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). ArcGIS. Johns Hopkins University. Available at: https://coronavirus.jhu.edu/map.html Accessed: 22.05.2023.
- Vitiello A, Ferrara F, Auti AM, et al. Advances in the Omicron variant development. J Intern Med. 2022;292(1):81-90. doi: 10.1111/joim.13478
- Приказ Министерства здравоохранения Российской Федерации от 13.01.2022 №8н «Об утверждении перечня медицинских противопоказаний к проведению профилактических прививок против новой коронавирусной инфекции СОVID-19» (Зарегистрирован 17.01.2022 №66893). Режим доступа: https://cdn.stopcoronovirus.ru/ai/doc/1229/attach/0001202201170016.pdf. Ссылка активна на 29.06.2023 [Prikaz Ministerstva zdravookhraneniia Rossiiskoi Federatsii ot 13.01.2022 №8n «Ob utverzhdenii perechnia meditsinskikh protivopokazanii k provedeniiu profilakticheskikh privivok protiv novoi koronavirusnoi infektsii SOVID-19» (Zaregistrirovan 17.01.2022 №66893). Available at: https://cdn.stopcoronovirus.ru/ai/doc/1229/attach/0001202201170016.pdf. Accessed: 29.06.2023 (in Russian)].
- Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 17 от 14.12.2022. Режим доступа: http://nasci.ru/?id=103858&download=1. Ссылка активна на 29.06.2023 [Vremennye metodicheskie rekomendatsii «Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19)». Versiia 17 ot 14.12.2022. Available at: http://nasci.ru/?id=103858&download=1. Accessed: 29.06.2023 (in Russian)].
- EMA. EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab). European Medicines Agency. 2021. Available at: https://www.ema.europa.eu/en/news/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimab-imdevimab. Accessed: 30.05.2022.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238-51. doi: 10.1056/NEJMoa2035002
- Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:665-76. doi: 10.1016/S0140-6736(22)00163-5
- Shen Y, Zheng F, Sun D, et al. Epidemiology and clinical course of COVID-19 in Shanghai, China. Emerg Microbes Infec. 2020;9(1):1537-45. doi: 10.1080/22221751.2020.1787103
- Çelik I, Öztürk R. From asymptomatic to critical illness: decoding various clinical stages of COVID-19. Turk J Med Sci. 2021;51:3284-300. doi: 10.3906/sag-2107-137
- O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021;385(13):1184-95. doi: 10.1056/NEJMoa2109682
Supplementary files
